PMC:7445716 / 77473-77720 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T640","span":{"begin":42,"end":45},"obj":"Body_part"},{"id":"T641","span":{"begin":141,"end":144},"obj":"Body_part"},{"id":"T642","span":{"begin":145,"end":153},"obj":"Body_part"}],"attributes":[{"id":"A640","pred":"fma_id","subj":"T640","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A641","pred":"fma_id","subj":"T641","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A642","pred":"fma_id","subj":"T642","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T712","span":{"begin":103,"end":111},"obj":"Disease"},{"id":"T713","span":{"begin":112,"end":115},"obj":"Disease"}],"attributes":[{"id":"A712","pred":"mondo_id","subj":"T712","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A713","pred":"mondo_id","subj":"T713","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T699","span":{"begin":214,"end":216},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T364","span":{"begin":145,"end":153},"obj":"Chemical"}],"attributes":[{"id":"A364","pred":"chebi_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1179","span":{"begin":102,"end":110},"obj":"Disease"}],"attributes":[{"id":"A1179","pred":"tao:has_database_id","subj":"1179","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-sentences","denotations":[{"id":"T462","span":{"begin":16,"end":116},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T792","span":{"begin":132,"end":153},"obj":"Phenotype"}],"attributes":[{"id":"A792","pred":"hp_id","subj":"T792","obj":"http://purl.obolibrary.org/obo/HP_0002922"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1164","span":{"begin":103,"end":111},"obj":"SP_7"},{"id":"T95046","span":{"begin":103,"end":111},"obj":"SP_7"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}

{"project":"2_test","denotations":[{"id":"32840686-31541214-63205845","span":{"begin":3,"end":5},"obj":"31541214"},{"id":"32840686-26948435-63205845","span":{"begin":3,"end":5},"obj":"26948435"},{"id":"32840686-30310069-63205845","span":{"begin":3,"end":5},"obj":"30310069"},{"id":"32840686-24163275-63205846","span":{"begin":10,"end":12},"obj":"24163275"},{"id":"32840686-31541214-63205847","span":{"begin":201,"end":203},"obj":"31541214"},{"id":"32840686-22612740-63205848","span":{"begin":205,"end":207},"obj":"22612740"},{"id":"32840686-26948435-63205849","span":{"begin":241,"end":243},"obj":"26948435"},{"id":"32840686-11306855-63205850","span":{"begin":245,"end":247},"obj":"11306855"}],"text":"ts [57–59, 66]. Similarly, the results of CSF analysis reflected typical neurochemical findings in non-COVID-19 GBS. In the latter, elevated CSF proteins and pleocytosis were described in about 50–80% [57, 78] and 11–15% cases, respectively [58, 7"}